The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth.
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …

Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …

Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related
deaths globally due, in part, to the majority of patients being diagnosed with intermediate or …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low
five-year survival rates leading to a substantial worldwide burden for healthcare systems …

The vascular endothelial growth factor (VEGF) family members, VEGF-A, placenta growth
factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated …

Abstract Background Long non-coding RNAs (lncRNAs) are crucial in the invasion,
angiogenesis, progression, and metastasis of hepatocellular carcinoma (HCC). The lncRNA …